Our data also indicate that the combined analysis of CDKN2A methylation and immunohistochemical staining for p16 expression might be an approach to distinguish HCC from non-HCC liver tumors and liver metastases. The gene discussed is CDKN2A; the disease is hepatocellular carcinoma.